Prognostic significance of PSA, Gleason score, bone metastases, clinical stage, ALP in patients with bone pain as the first manifestation of prostate cancer
LI Yi-fei,GUO Jian-ming,XU Lei
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2013.19.016
2013-01-01
Abstract:Objective To analyze the clinical characteristics of prostate cancer with bone pain as the first clinical manifestation retrospectively, the aim of this study was to evaluate the prognostic significance of the age, initial serum level PSA, Gleason score, bone metastases, clinical stage, ALP in the overall survival in patients with bone pain as the first manifestation of prostate cancer. Methods During the time period from 2003 to 2010, a total of 51 patients with newly diagnosed, histologically confirmed prostate cancer, histological diagnosis was carried through the transrectal ultrasonography guided biopsy and carried on Gleason score assessment. Metastases were confirmed by positive bone scintigraphy with 555-925 MBq99mTc-MDP using Emission computed Tomography, some of which were identified by pathology of excision of metastatic bone tumor or bone marrow aspiration, all of this patients had been treated by androgen deprivation treatment, probe into the impact of the age, initial serum level PSA, Gleason score, bone metastases, clinical stage, ALP on the overall survival. Results The incidence of the bone pain as the first clinical manifestation of prostate cancer was 92.2%(47/51), the metastasis of pelvis, lumbar was most common, 21.5%, 29.0% respectively, at a median follow-up of 32.1months, 20 patients had died, the median overall survival after maximal androgen blockade was 24.4 months and was significantly longer if the age was less than 71 years(29.1 months vs. 23.1 months, P=0.0169) and Gleason score(2-6, 7, 8-10) was lower(62.4 months vs. 35.1 months vs. 12.5 months, P=0.0173), bone metastases was less than 6 sites(36.1 months vs. 4.4 months, P=0.0144),only bone metastases(Compared to bone and nodes or organs metastases 23.7 months vs. 4.4 months, P=0.0304),clinical stage was less than stage T2(62.4 months vs. 22.8 months, P=0.0257), ALP was in the normal rang(37.0 months vs. 19.0 months, P=0.0151), it had not demonstrated statistically significant interactions of overall survival with the initial PSA level.Mean time±SD to PSA relapse after first-line MAB was(17.6±8.3) months, of the 44 patients(PSA relapse) treated with second-line MAB, 24(54.5%) were considered to be responders. Conclusions Gleason score, the presence of bone, lymph nodes and liver, visceral metastases, clinical stage, ALP significantly predict OS in patients with bone pain as the first clinical manifestation. Maximum androgen blockade is an effective treatment, some patients can also benefit from the second-line treatment after PSA relapse of the first-line hormonal treatment.